Anti-clotting treatment apixaban outperforms Lovenox in study

03/4/2010 | Reuters

Apixaban beat standard treatment Lovenox in preventing blood clots without increasing the risk of bleeding during a late-stage trial in patients who underwent knee surgery. Apixaban is a product of Pfizer and Bristol-Myers Squibb, which plan to submit the drug for European approval this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT